Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PrOD for HCV GT-1b in Hemodialysis Patients
NCT02874066Phase 4Completed
- Sponsor
- National Taiwan University Hospital
- Start
- Mar 2017
- Primary completion
- Oct 2018
- Modality
- Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ombitasvir, paritaprevir, ritonavir and dasabuvir in hepatitis C (HCV), sponsored by National Taiwan University Hospital. Primary endpoint: Sustained Virologic Response at 12 weeks post-treatment. Started Mar 2017; status: completed.
02
Drugs
ombitasvirparitaprevirritonavirdasabuvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02874066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02874066.